James Hansen, DO
Interventional Cardiology · Doylestown, PANPI 1275769846
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,401 of the $5,912 with a category attached, or 74.4%. 20 manufacturers reported payments, led by Edwards Lifesciences at 45.7% of the total. 2025 is the largest year on record at $2,290, more than ten times the $61 reported in 2019. That places this record below the midpoint for interventional cardiology clinicians in PA, where the typical reported total is $6,486.
Across 138 payments — averaging $42.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$3K
- Medtronic$818
- Abbott$576
- Novartis$331
- Abiomed$311
- E.r. Squibb & Sons, L.L.C.$198
- plus $974 from 14 others
Across 3 payments — averaging $12,839 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$38K
- Novartis$387
What the payments were for
- Travel & lodging$1,51126%
- Food & beverage$4,40174%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 23 | $2,704 |
| Medtronic(2 entities) | 8 | $818 |
| Abbott | 9 | $576 |
| Novartis | 26 | $331 |
| Abiomed | 8 | $311 |
| E.r. Squibb & Sons, L.L.C. | 12 | $198 |
| Novo Nordisk | 9 | $169 |
| Amgen | 8 | $157 |
| AstraZeneca | 8 | $140 |
| Johnson & Johnson | 4 | $76 |
| Boehringer Ingelheim | 3 | $67 |
| Shockwave Medical, Inc | 2 | $64 |
| Boston Scientific | 4 | $63 |
| Merck | 3 | $51 |
| Pfizer | 3 | $49 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $49 |
| Cardiovascular Systems Inc. | 2 | $31 |
| BD | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,912 in reported general payments places this provider in the 45th percentile of 281 interventional cardiology providers in Pennsylvania.
See all interventional cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 158 | $163,831 |
| FarxigaDapagliflozin Propanediol | 57 | $50,599 |
| OzempicSemaglutide | 43 | $42,503 |
| EntrestoSacubitril/Valsartan | 29 | $36,992 |
| JardianceEmpagliflozin | 25 | $21,260 |
| Repatha SureclickEvolocumab | 12 | $17,935 |
| Atorvastatin Calcium | 402 | $4,845 |
| Icosapent Ethyl | 24 | $4,419 |
| Metoprolol Succinate | 296 | $4,038 |
| Ezetimibe | 172 | $2,650 |
| Rosuvastatin Calcium | 114 | $1,688 |
| Diltiazem 24hr Er (La)Diltiazem Hcl | 31 | $1,189 |
| Carvedilol | 119 | $1,036 |
| Valsartan | 32 | $714 |
| Furosemide | 185 | $679 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $49 | $163,831158 claims |
| AstraZenecaFarxiga | $140 | $50,59957 claims |
| Novo NordiskOzempic | $169 | $42,50343 claims |
| NovartisEntresto | $331 | $36,99229 claims |
| Boehringer IngelheimJardiance | $67 | $21,26025 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 281 interventional cardiology providers in Pennsylvania.
Other interventional cardiology in Doylestown
- Nishant SethiScranton$1.3M
- Matthew BeckerErie$1M
- William GrayWynnewood$753K
- Jon GeorgePhiladelphia$637K
- Shailendra SinghAllentown$470K
- Sanjog KalraPhiladelphia$444K
- James HarveyChambersburg$442K
- Taisei KobayashiPhiladelphia$384K
- Antonis PratsosBroomall$377K
- Ronald FieldsNew Hope$373K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.